Sanofi and Roche have joined forces in France to drive adoption of a connected add-on for disposable insulin pens. The partners will jointly develop a scientific program for physicians and retail pharmacists around the Biocorp product.
Almost two years ago, Biocorp (who are partnered with Roche Diabetes France) gave Sanofi rights to distribute Mallya, which adds smart features to insulin pens, while Biocorp was tasked with developing an exclusive version of the connected technology for Sanofi’s SoloStar delivery devices.
Mallya automatically collects the insulin doses selected by the patient, creating a record of their injection history. Through a connection with Accu-Chek blood glucose meters, the Gluci-Chek mobile application and the Roche Diabetes Care Platform, the injection data can sit alongside other information, such as the patient’s blood glucose results.
Sanofi and Roche see the scientific program as a way to drive adoption of the technology by explaining how it connects to a broader ecosystem through some planned physical and virtual events along the theme of “Insulin therapy and connected ecosystem for the benefit of Type 2 diabetes patients”.
To read more, CLICK HERE.
